Is Rucaparib an imported drug or a domestically produced drug?

Rucaparib (Rucaparib) is an innovative PARP inhibitor used for the maintenance treatment of recurrent or advanced ovarian cancer. Its mechanism of action is by inhibiting the poly(ADP-ribose) polymerase (PARP) family, blocking the repair of damaged DNA in cancer cells, making cancer cells unable to survive. This targeted therapy concept is a milestone in the field of precision anti-cancer, and is especially suitable for patients carrying BRCA gene mutations or homologous recombination repair deficiency (HRD).

Globally, rucapanib was developed by the American companyClovis Oncology. It is an original drug that has been approved for marketing in the United States, Europe, Japan and other countries, and has been included in many international cancer treatment guidelines. It especially occupies an important position in the maintenance treatment of recurrent ovarian cancer. However, rucapanib has not yet been approved for marketing by the National Medical Products Administration (NMPA) in China. This means that there is neither a domestic version of Rucapani nor official import channels for routine use in the domestic market. Therefore, from the perspective of law and drug classification, rucapanib is neither a domestic drug nor an imported drug in China, and can only be obtained through special channels such as clinical trials or individual import applications.

This current situation has brought certain restrictions on the treatment options for domestic patients. For ovarian cancer patients who require PARP inhibitor maintenance therapy, the inability to routinely obtain rucaparib locally means that clinicians must develop alternative treatment options based on existing drugs and guidelines, such as using other approved PARP inhibitors (olaparib, niraparib, etc.), or obtaining drugs through international pharmaceutical assistance programs. At the same time, the lack of rucapanib on the market also suggests that there is still room for improvement in the approval and clinical introduction of new targeted drugs in China, especially in precision medicine and personalized anti-cancer treatment.

Reference materials:https://www.drugs.com/mtm/rucaparib.html